Remogliflozin etabonate

SKU: orb1695501

Description

Remogliflozin etabonate is a prodrug metabolized to the active SGLT2 inhibitor remogliflozin. It shows high selectivity for inhibiting SGLT2 over SGLT1, as evidenced by its Ki values against human and rat isoforms. This compound is utilized in preclinical research to investigate SGLT2 function in diabetes and metabolic disease models.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 442201-24-3
• MW: 522.59
• Purity: 99.00% (May vary between batches)
• Formula: C₂₆H₃₈N₂O₉
• SMILES: CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O
• Target: SGLT
• Solubility: DMSO:90 mg/mL (172.22 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.31 mM)

Bioactivity

• Target IC50:
  SGLT2 (rat):2.14 μM (Ki)|SGLT1 (human):43.1 μM (Ki)|SGLT1 (rat):8.57 μM (Ki)|SGLT2 (human):1.95 μM (Ki)
• In Vivo:
  Oral administration of Remogliflozin etabonate (10-30 mg/kg) dose-dependently reduces the levels of FPG and GHb. Oral administration of Remogliflozin etabonate (3-30 mg/kg) dose-dependently increases urine volume and urinary glucose excretion.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

GSK189075, GSK-189075, GSK189075A, GSK-189075A, GSK 189075, GSK 189075A, Remogliflozin etabonate, SGLT2

Compound Identifiers

PubChem CID

9871420